{"component": "definition", "props": {"groups": [{"samples": [{"hash": "leQAVcs6sgx", "uri": "/contracts/leQAVcs6sgx#initial-indications", "label": "Confidential Agreement (Alvotech Lux Holdings S.A.S.)", "score": 32.9671457906, "published": true}, {"hash": "jkJJ7cVZurZ", "uri": "/contracts/jkJJ7cVZurZ#initial-indications", "label": "Confidential Agreement (Alvotech Lux Holdings S.A.S.)", "score": 32.9671457906, "published": true}, {"hash": "hYWDLmEig03", "uri": "/contracts/hYWDLmEig03#initial-indications", "label": "Confidential Agreement (Alvotech Lux Holdings S.A.S.)", "score": 32.9671457906, "published": true}], "size": 6, "snippet_links": [{"key": "eu-countries", "type": "definition", "offset": [48, 60]}, {"key": "the-territory", "type": "clause", "offset": [64, 77]}, {"key": "at-the-effective-date", "type": "clause", "offset": [78, 99]}, {"key": "additional-indications", "type": "clause", "offset": [118, 140]}], "snippet": "means all indications approved for [***] in the EU countries of the Territory at the Effective Date and excluding any Additional Indications.", "hash": "35e8879254eb64b4b3c64b9efc13c9f3", "id": 1}, {"samples": [{"hash": "jUJwgNQffnr", "uri": "/contracts/jUJwgNQffnr#initial-indications", "label": "Collaboration and License Agreement (Affymax Inc)", "score": 21.0, "published": true}, {"hash": "g89inQlCGBm", "uri": "/contracts/g89inQlCGBm#initial-indications", "label": "Collaboration and License Agreement (Affymax Inc)", "score": 21.0, "published": true}, {"hash": "g0KB4Ig1iCI", "uri": "/contracts/g0KB4Ig1iCI#initial-indications", "label": "Collaboration and License Agreement (Affymax Inc)", "score": 21.0, "published": true}], "size": 6, "snippet_links": [{"key": "oncology-indications", "type": "definition", "offset": [10, 30]}, {"key": "renal-indications", "type": "definition", "offset": [39, 56]}], "snippet": "means the Oncology Indications and the Renal Indications.", "hash": "3d11778cf4447a6e1b9e179fb9917c07", "id": 2}, {"samples": [{"hash": "1qb4WEVRiz6", "uri": "/contracts/1qb4WEVRiz6#initial-indications", "label": "Collaboration and License Agreement (TESARO, Inc.)", "score": 26.5927446954, "published": true}, {"hash": "9Dl76blRmTW", "uri": "https://stockdeck.io/wp-content/uploads/TSRO-Form-10Q-Presentation-30-June-2016.pdf", "label": "stockdeck.io", "score": 6.7138945927, "published": false}], "size": 5, "snippet_links": [], "snippet": "means [***].", "hash": "42145ccc68badf480a8ed917c57dd5fc", "id": 3}, {"samples": [{"hash": "hVeyhcxhHKX", "uri": "/contracts/hVeyhcxhHKX#initial-indications", "label": "Confidentiality Agreement (Sucampo Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "fy1KL448wUe", "uri": "/contracts/fy1KL448wUe#initial-indications", "label": "Collaboration and License Agreement (Sucampo Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "fbffL2QHwh5", "uri": "/contracts/fbffL2QHwh5#initial-indications", "label": "Collaboration and License Agreement (Sucampo Pharmaceuticals, Inc.)", "score": 21.0, "published": true}], "size": 4, "snippet_links": [{"key": "not-limited", "type": "clause", "offset": [54, 65]}, {"key": "the-product", "type": "clause", "offset": [97, 108]}], "snippet": "means all gastroenterology indications, including but not limited to, Constipation and C-IBS for the Product.", "hash": "57ef5af521506af2b7dca7d022683320", "id": 4}, {"samples": [{"hash": "2ez19I7ilry", "uri": "/contracts/2ez19I7ilry#initial-indications", "label": "Exclusive License and Collaboration Agreement (Hutchison China MediTech LTD)", "score": 30.4072553046, "published": true}, {"hash": "fIgWtHiCQWi", "uri": "/contracts/fIgWtHiCQWi#initial-indications", "label": "Exclusive License and Collaboration Agreement (Hutchison China MediTech LTD)", "score": 30.3305954825, "published": true}, {"hash": "10sshq3DEr7", "uri": "/contracts/10sshq3DEr7#initial-indications", "label": "Exclusive License and Collaboration Agreement (Hutchison China MediTech LTD)", "score": 26.787816564, "published": true}], "size": 4, "snippet_links": [{"key": "colorectal-cancer", "type": "clause", "offset": [19, 36]}, {"key": "small-cell", "type": "definition", "offset": [55, 65]}, {"key": "lung-cancer", "type": "definition", "offset": [66, 77]}], "snippet": "means (a) 3rd line colorectal cancer, (b) 3rd line non-small cell lung cancer and (c) 2nd line advanced gastric cancer. Each of the Initial Indications shall be an \u201cInitial Indication\u201d hereunder.", "hash": "7c68e0f2d856b282066c041f918dc7b2", "id": 5}, {"samples": [{"hash": "ktSdNvXeQ68", "uri": "/contracts/ktSdNvXeQ68#initial-indications", "label": "Licence and Development Agreement", "score": 29.340862423, "published": true}, {"hash": "4CLqKVIgHOF", "uri": "/contracts/4CLqKVIgHOF#initial-indications", "label": "Licence and Development Agreement (Orchard Rx LTD)", "score": 27.7556468172, "published": true}, {"hash": "h6LnDqocl4S", "uri": "/contracts/h6LnDqocl4S#initial-indications", "label": "Licence and Development Agreement (Orchard Rx LTD)", "score": 27.7145790554, "published": true}], "size": 3, "snippet_links": [], "snippet": "means ADA-SCID and MPS-IIIA;", "hash": "d338ad12c66c8b1ffc950ab36687ea3f", "id": 6}, {"samples": [{"hash": "dh0exlyUbJm", "uri": "/contracts/dh0exlyUbJm#initial-indications", "label": "Development and License Agreement (Onconova Therapeutics, Inc.)", "score": 24.5427789185, "published": true}, {"hash": "dI96LsRkx79", "uri": "/contracts/dI96LsRkx79#initial-indications", "label": "Development and License Agreement (Onconova Therapeutics, Inc.)", "score": 24.4496919918, "published": true}, {"hash": "1SHdi0huJQi", "uri": "/contracts/1SHdi0huJQi#initial-indications", "label": "Development and License Agreement (Onconova Therapeutics, Inc.)", "score": 24.3347022587, "published": true}], "size": 3, "snippet_links": [], "snippet": "means MDS Oral, MDS IV and Pancreatic Cancer.", "hash": "3038eaf6e9b8ff5649070ef8ac1c61c5", "id": 7}, {"samples": [{"hash": "gcKd0goiDQP", "uri": "/contracts/gcKd0goiDQP#initial-indications", "label": "License Agreement (Gossamer Bio, Inc.)", "score": 29.9691991786, "published": true}, {"hash": "6gaFG7a4C9A", "uri": "/contracts/6gaFG7a4C9A#initial-indications", "label": "License Agreement (Gossamer Bio, Inc.)", "score": 29.7748117728, "published": true}, {"hash": "iqDGJyChEJC", "uri": "/contracts/iqDGJyChEJC#initial-indications", "label": "License Agreement (Aerpio Pharmaceuticals, Inc.)", "score": 29.4791238877, "published": true}], "size": 3, "snippet_links": [{"key": "maintenance-in", "type": "clause", "offset": [59, 73]}, {"key": "ulcerative-colitis", "type": "definition", "offset": [74, 92]}, {"key": "related-to", "type": "clause", "offset": [123, 133]}, {"key": "inflammatory-bowel-disease", "type": "definition", "offset": [134, 160]}, {"key": "other-indication", "type": "definition", "offset": [282, 298]}, {"key": "development-plan", "type": "definition", "offset": [311, 327]}, {"key": "to-this-agreement", "type": "clause", "offset": [340, 357]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [358, 382]}], "snippet": "means each of the following Indications: (i) induction and maintenance in ulcerative colitis (or similar Indication solely related to inflammatory bowel disease (\u201cIBD\u201d)), (ii) induction and maintenance in Crohn\u2019s Disease (or similar Indication solely related to IBD), and (iii) any other Indication for which a Development Plan is attached to this Agreement as of the Effective Date.", "hash": "d4af11454b501a1eceb10b03292733cd", "id": 8}, {"samples": [{"hash": "GSSAIAx4hz", "uri": "/contracts/GSSAIAx4hz#initial-indications", "label": "License and Collaboration Agreement (Spectrum Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "4sWzML2dJx1", "uri": "/contracts/4sWzML2dJx1#initial-indications", "label": "License and Collaboration Agreement (Spectrum Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "5p1ziDVeAee", "uri": "https://investor.sppirx.com/index.php/static-files/91880f96-5959-4bdf-9dd1-41f8b1322e8d", "label": "investor.sppirx.com", "score": 7.8446269678, "published": false}], "size": 3, "snippet_links": [{"key": "contract-products", "type": "definition", "offset": [32, 49]}, {"key": "prostate-cancer", "type": "clause", "offset": [58, 73]}], "snippet": "means the use of D-63153 and/or Contract Products for (i) prostate cancer; (ii) benign prostate hyperplasia (BPH); and (iii) endometriosis.", "hash": "c269864f18c5d4c106d2dfa9e6d2ec66", "id": 9}, {"samples": [{"hash": "8XxQElTBgLG", "uri": "/contracts/8XxQElTBgLG#initial-indications", "label": "License and Collaboration Agreement (Ovid Therapeutics Inc.)", "score": 28.2717316906, "published": true}, {"hash": "7QX0wINzbpz", "uri": "/contracts/7QX0wINzbpz#initial-indications", "label": "License and Collaboration Agreement (Ovid Therapeutics Inc.)", "score": 28.2142368241, "published": true}, {"hash": "2q6IGzYY5NL", "uri": "http://investors.ovidrx.com/static-files/b343e4ef-c846-44df-b4f0-37d8b6372a3e", "label": "investors.ovidrx.com", "score": 10.1704312115, "published": false}], "size": 3, "snippet_links": [], "snippet": "means, as to the Compound: (a) Dravet Syndrome (DS); (b) Tuberous Sclerosis (TSC); and (c) Lennox-Gastaut Syndrome (LGS).", "hash": "a36b5cceef1bc647e88159d1fecf4524", "id": 10}], "next_curs": "CmASWmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjwLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIcaW5pdGlhbC1pbmRpY2F0aW9ucyMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "Initial Indications", "size": 91, "snippet": "means all indications approved for [***] in the EU countries of the Territory at the Effective Date and excluding any Additional Indications.", "id": "initial-indications", "examples": ["The Research Program is directed to: (i) the Research by Company of Cue Biologics up to Proof of Mechanism for each of the <strong>Initial Indications</strong>; and, subject to Section 2.2.2; (ii) the further Research and/or Development by Merck of Proposed Product Candidates.", "If such termination by Lilly is solely due to \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2019\u2587 inability to obtain a required Third Party license, and if Lilly has not yet viewed the proof of concept study data for any of the <strong>Initial Indications</strong>, then within thirty (30) days of the effective date of termination, \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 will pay Lilly Two Million U.S. Dollars ($2,000,000) in consideration for Lilly\u2019s collaborative efforts.", "The JEC shall review such recommendations and determine: (A) whether to designate such Development Candidate as a Product Candidate; (B) if so, in which Indication(s) to further Develop such Development Candidate as a Product Candidate for the purpose of obtaining Regulatory Approval and (C) the list of Related Indications for such Indication(s) (other than the Related Indications for the <strong>Initial Indications</strong> as of the Effective Date, which are set forth in the Joint Exploratory Development Plan).", "Following the successful completion by Ablynx of the Initial Development Activities in accordance with the Initial Development Plan and Budget and AbbVie proceeding with the In-Licensing, AbbVie shall use Commercially Reasonable Efforts to obtain all Regulatory Approvals for the initial Licensed Product containing or comprising the Lead Compound for the <strong>Initial Indications</strong> in accordance with the applicable Development Plan.", "The Parties shall Develop the Product in the <strong>Initial Indications</strong> in the Licensed Territory as provided in this Article 3 and in accordance with the then-current U.S. Development Plan.", "After AbbVie proceeds with the In-Licensing, AbbVie shall use Commercially Reasonable Efforts to Commercialize a Licensed Product for the <strong>Initial Indications</strong> in each Major Market following receipt of Regulatory Approval therefor in each such Major Market.", "Takeda and SPI shall each ensure that all marketing, promotion and sale of the Products for the <strong>Initial Indications</strong> and, if applicable, Additional Indications and/or New Formulations in the Initial Territory as permitted hereunder complies with the conditions and requirements of applicable Regulatory Approvals, and with all Applicable Regulations in the Initial Territory.", "Ablynx shall use Commercially Reasonable Efforts in undertaking the Development activities (including Initial Development Activities) for the initial Licensed Product containing or comprising the Lead Compound for the <strong>Initial Indications</strong> in those countries in the Territory set forth in the Initial Development Plan and Budget.", "Takeda shall conduct and fund all Post Marketing Surveillance on the Products for the <strong>Initial Indications</strong> and, if applicable, Additional Indications and/or New Formulations in the Initial Territory.", "Subject to the terms and conditions of this Agreement and the SAG Agreement and during their terms, SPI hereby grants to Takeda an exclusive, non-transferable, limited license, with a right of sublicense to Takeda Affiliates, to use the Licensed Trademarks to advertise, market, promote and sell the Products for the <strong>Initial Indications</strong> and, if applicable, Additional Indications and/or New Formulations in the Initial Territory."], "related": [["initial-indication", "Initial Indication", "Initial Indication"], ["additional-indication", "Additional Indication", "Additional Indication"], ["geographical-indication", "geographical indication", "geographical indication"], ["collaboration-product", "Collaboration Product", "Collaboration Product"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"]], "related_snippets": [], "updated": "2025-07-06T21:58:36+00:00"}, "json": true, "cursor": ""}}